Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC).

被引：3

作者：

Adams, Sylvia

Dieras, Veronique

Barrios, Carlos H.

Winer, Eric P.

Schneeweiss, Andreas

Iwata, Hiroji

Loi, Sherene

Patel, Sheetal

Henschel, Volkmar

Chui, Stephen Y.

Rugo, Hope S.

Emens, Leisha A.

Schmid, Peter

机构：

[1] NYU, Inst Canc, New York, NY USA

[2] Ctr Eugene Marquis, Rennes, France

[3] PUCRS Sch Med, Porto Alegre, RS, Brazil

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Genentech Inc, San Francisco, CA 94080 USA

[10] F Hoffmann La Roche Ltd, Basel, Switzerland

[11] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[12] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

[13] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.1067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1067

引用

页数：2